Reference
What is Cagrilintide?
Cagrilintide is an analogue of amylin, a peptide hormone secreted alongside insulin. Amylin is a different molecule from GLP-1 and from GIP, so cagrilintide sits in a separate family from the incretin analogues it is often mentioned beside.
Classification
| Type | Peptide |
| Family | Amylin analogue |
| Origin | Developed by Novo Nordisk |
| Supplied as | Lyophilised powder in a sealed vial |
Natural human amylin has an awkward property for a drug: it aggregates readily, forming insoluble fibrils. Analogues in this class are designed largely around preventing that, which is why their sequences diverge from the natural hormone more than a simple stability modification would require.
What this page does not cover
Nothing here describes what Cagrilintide does, what it is used for, or whether it is safe. We publish analytical results and ship parcels; we give no guidance on dosing, preparation or use, and that applies to our reference pages as much as to the product pages. The person to ask about any of that is a registered prescriber.
Where it came from
Cagrilintide is an amylin analogue, and its design problem was not survival in blood but a tendency of the natural hormone to clump.
First described around 2018 — Denmark. When was cagrilintide created?
More on Cagrilintide
- Cagrilintide — prices and sizes
- Buying Cagrilintide in New Zealand
- When was Cagrilintide discovered?
See Cagrilintide in the range · What is a peptide? · Discovery timeline · All reference
